Skip to main content
Erschienen in: Rheumatology International 10/2013

01.10.2013 | Original Article

Organ damage in high-risk patients with systemic and incomplete lupus syndromes

verfasst von: Nancy J. Olsen, Maha Yousif, Azza Mutwally, Melinda Cory, Nada Elmagboul, David R. Karp

Erschienen in: Rheumatology International | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to characterize organ damage in lupus patients enrolled in Dallas Regional Autoimmune Disease Registry (DRADR). Retrospective chart review was carried out on 99 patients with four or more diagnostic criteria for systemic lupus erythematosus (SLE) and 15 with less than four of these criteria, who were designated as having incomplete lupus erythematosus (ILE). The majority of patients (84 %) were African American or Hispanic/Latino; mean disease duration was 9.5 years. The mean damage score was 1.57 (range 0–8), and a damage score greater than 0 was present in 64 % of the patients. The ILE group had lower mean damage scores (0.67) than the SLE group (1.67; P = 0.04), explained in part by the shorter disease duration in the ILE patients (4.33 vs. 10.24 years; P = 0.003). The most prevalent damage category was renal, present in 24 % of patients. Malignancies occurred in individuals who were significantly older than those who had renal or peripheral vascular damage (P = 0.0007). The findings confirm clinical impressions that DRADR includes a high-risk lupus population. The ILE patients have less damage but also shorter disease duration, suggesting that this might represent an earlier disease stage. These results are consistent with the hypothesis that ILE patients include a subset that is likely to experience progressive organ damage. Longitudinal study of these patients has significant likelihood of tracking the changes that are correlated with disease progression to SLE.
Literatur
1.
Zurück zum Zitat Vilá LM, Alarcón GS, McGwin G, Friedman AW, Baethge BA, Bastian HM, Fessler BJ, Reveille JD, Group LS (2004) Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology (Oxford) 43:358–363CrossRef Vilá LM, Alarcón GS, McGwin G, Friedman AW, Baethge BA, Bastian HM, Fessler BJ, Reveille JD, Group LS (2004) Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology (Oxford) 43:358–363CrossRef
2.
Zurück zum Zitat Korbet SM, Schwartz MM, Evans J, Lewis EJ, Group CS (2007) Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 18:244–254PubMedCrossRef Korbet SM, Schwartz MM, Evans J, Lewis EJ, Group CS (2007) Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 18:244–254PubMedCrossRef
3.
Zurück zum Zitat Tan E, Cohen A, Fries J, Masi A, McShane D, Rothfield N, Schaller J, Talal N, Winchester R (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef Tan E, Cohen A, Fries J, Masi A, McShane D, Rothfield N, Schaller J, Talal N, Winchester R (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef
4.
Zurück zum Zitat Ståhl Hallengren C, Nived O, Sturfelt G (2004) Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus 13:85–88PubMedCrossRef Ståhl Hallengren C, Nived O, Sturfelt G (2004) Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus 13:85–88PubMedCrossRef
5.
Zurück zum Zitat Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369PubMedCrossRef Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369PubMedCrossRef
6.
Zurück zum Zitat Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, Hanly JG, Isenberg DA, Kalunian K, Nived O, Petri M, Sanchez-Guerrero J, Snaith M, Sturfelt G (1997) The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 40:809–813PubMedCrossRef Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, Hanly JG, Isenberg DA, Kalunian K, Nived O, Petri M, Sanchez-Guerrero J, Snaith M, Sturfelt G (1997) The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 40:809–813PubMedCrossRef
7.
Zurück zum Zitat Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, Listing J, Nicola PJ, Tarp U, Zink A, Askling J (2010) EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 69:1596–1602PubMedCrossRef Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, Listing J, Nicola PJ, Tarp U, Zink A, Askling J (2010) EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 69:1596–1602PubMedCrossRef
8.
Zurück zum Zitat Wandstrat A, Carr-Johnson F, Branch V, Gray H, Fairhurst A, Reimold A, Karp D, Wakeland E, Olsen N (2006) Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmun 27:153–160PubMedCrossRef Wandstrat A, Carr-Johnson F, Branch V, Gray H, Fairhurst A, Reimold A, Karp D, Wakeland E, Olsen N (2006) Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmun 27:153–160PubMedCrossRef
9.
Zurück zum Zitat Vilá LM, Alarcón GS, McGwin G, Bastian HM, Fessler BJ, Reveille JD, Group LS (2005) Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheumatol 32:2150–2155PubMed Vilá LM, Alarcón GS, McGwin G, Bastian HM, Fessler BJ, Reveille JD, Group LS (2005) Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheumatol 32:2150–2155PubMed
10.
Zurück zum Zitat Kamen DL, Barron M, Parker TM, Shaftman SR, Bruner GR, Aberle T, James JA, Scofield RH, Harley JB, Gilkeson GS (2008) Autoantibody prevalence and lupus characteristics in a unique African American population. Arthritis Rheum 58:1237–1247PubMedCrossRef Kamen DL, Barron M, Parker TM, Shaftman SR, Bruner GR, Aberle T, James JA, Scofield RH, Harley JB, Gilkeson GS (2008) Autoantibody prevalence and lupus characteristics in a unique African American population. Arthritis Rheum 58:1237–1247PubMedCrossRef
11.
Zurück zum Zitat Sung YK, Hur NW, Sinskey JL, Park D, Bae SC (2007) Assessment of damage in Korean patients with systemic lupus erythematosus. J Rheumatol 34:987–991PubMed Sung YK, Hur NW, Sinskey JL, Park D, Bae SC (2007) Assessment of damage in Korean patients with systemic lupus erythematosus. J Rheumatol 34:987–991PubMed
12.
Zurück zum Zitat Alarcón GS, McGwin G, Petri M, Reveille JD, Ramsey-Goldman R, Kimberly RP, Group PS (2002) Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 11:95–101PubMed Alarcón GS, McGwin G, Petri M, Reveille JD, Ramsey-Goldman R, Kimberly RP, Group PS (2002) Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 11:95–101PubMed
13.
Zurück zum Zitat Zonana-Nacach A, Barr SG, Magder LS, Petri M (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43:1801–1808PubMedCrossRef Zonana-Nacach A, Barr SG, Magder LS, Petri M (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43:1801–1808PubMedCrossRef
14.
Zurück zum Zitat Laustrup H, Voss A, Green A, Junker P (2010) SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study. Lupus 19:239–246PubMedCrossRef Laustrup H, Voss A, Green A, Junker P (2010) SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study. Lupus 19:239–246PubMedCrossRef
15.
Zurück zum Zitat Grönhagen CM, Fored CM, Granath F, Nyberg F (2011) Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1,088 patients in Sweden. Br J Dermatol 164:1335–1341PubMedCrossRef Grönhagen CM, Fored CM, Granath F, Nyberg F (2011) Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1,088 patients in Sweden. Br J Dermatol 164:1335–1341PubMedCrossRef
16.
Zurück zum Zitat Laustrup H, Voss A, Green A, Junker P (2009) Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. Scand J Rheumatol 38:128–132PubMedCrossRef Laustrup H, Voss A, Green A, Junker P (2009) Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. Scand J Rheumatol 38:128–132PubMedCrossRef
17.
Zurück zum Zitat Chambers SA, Allen E, Rahman A, Isenberg D (2009) Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 48:673–675CrossRef Chambers SA, Allen E, Rahman A, Isenberg D (2009) Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 48:673–675CrossRef
18.
Zurück zum Zitat Mok CC, Ho CT, Wong RW, Lau CS (2003) Damage accrual in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 30:1513–1519PubMed Mok CC, Ho CT, Wong RW, Lau CS (2003) Damage accrual in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 30:1513–1519PubMed
19.
Zurück zum Zitat Rabbani MA, Habib HB, Islam M, Ahmad B, Shah SM, Tahir S, Merchant D, Ahmad A (2010) Early renal damage assessed by the SLICC/ACR damage index is predictor of severe outcome in lupus patients in Pakistan. Lupus 19:1573–1578PubMedCrossRef Rabbani MA, Habib HB, Islam M, Ahmad B, Shah SM, Tahir S, Merchant D, Ahmad A (2010) Early renal damage assessed by the SLICC/ACR damage index is predictor of severe outcome in lupus patients in Pakistan. Lupus 19:1573–1578PubMedCrossRef
20.
Zurück zum Zitat Danila MI, Pons-Estel GJ, Zhang J, Vilá LM, Reveille JD, Alarcón GS (2009) Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 48:542–545CrossRef Danila MI, Pons-Estel GJ, Zhang J, Vilá LM, Reveille JD, Alarcón GS (2009) Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 48:542–545CrossRef
21.
Zurück zum Zitat Boya P, Gonzalez-Polo RA, Poncet D, Andreau K, Vieira HL, Roumier T, Perfettini JL, Kroemer G (2003) Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 22:3927–3936PubMedCrossRef Boya P, Gonzalez-Polo RA, Poncet D, Andreau K, Vieira HL, Roumier T, Perfettini JL, Kroemer G (2003) Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 22:3927–3936PubMedCrossRef
22.
Zurück zum Zitat Lightstone L (2013) Minimising steroids in lupus nephritis—will B cell depletion pave the way? Lupus 22:390–399PubMedCrossRef Lightstone L (2013) Minimising steroids in lupus nephritis—will B cell depletion pave the way? Lupus 22:390–399PubMedCrossRef
23.
Zurück zum Zitat Petri M, Purvey S, Fang H, Magder LS (2012) Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 64:4021–4028PubMedCrossRef Petri M, Purvey S, Fang H, Magder LS (2012) Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 64:4021–4028PubMedCrossRef
Metadaten
Titel
Organ damage in high-risk patients with systemic and incomplete lupus syndromes
verfasst von
Nancy J. Olsen
Maha Yousif
Azza Mutwally
Melinda Cory
Nada Elmagboul
David R. Karp
Publikationsdatum
01.10.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 10/2013
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2783-3

Weitere Artikel der Ausgabe 10/2013

Rheumatology International 10/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.